ACT DMD Update with PTC (February 2014) On February 5, 2014, Dr. Robert Spiegel, Chief Medical Officer at PTC Therapeutics, presented an update about PTC’s Phase 3 study of ataluren, now known as the Ataluren Confirmatory Trial in DMD (ACT DMD). Research & Clinical Trial Webinars,Webinars 11 years ago You may also like 1:06:10 COVID-19 & Duchenne: What you need to know (March 19, 2020) 5 years ago Care Webinars,COVID-19 Webinars,Webinars 51:41 Teen & Young Adult Trial Participation in Duchenne – Industry & Community Perspectives (March 4, 2020) 5 years ago Research & Clinical Trial Webinars,Webinars 1:02:48 Connect with the Experts: Cardiac Care & Research (February 27, 2020) 5 years ago Care Webinars,Research & Clinical Trial Webinars,Webinars 29:46 Update on Investigational Suvodirsen in Duchenne Muscular Dystrophy (December 2019) 5 years ago Research & Clinical Trial Webinars,Webinars 1:17:48 Better Todays. Stronger Tomorrows. (December 2019) 5 years ago Care Webinars,Research & Clinical Trial Webinars,Webinars 35:37 NS Pharma Provides Viltolarsen Update (November 2019) 5 years ago Research & Clinical Trial Webinars,Webinars 47:13 DYSTANCE 51, a Phase 2/3 Clinical Trial of Investigational Suvodirsen in Duchenne (October 2019) 5 years ago Research & Clinical Trial Webinars,Webinars 52:44 Community Discussion with Sarepta Therapeutics (August 2019) 5 years ago Research & Clinical Trial Webinars,Webinars «1…1213141516…25»Page 14 of 25
by: Parent Project Muscular Dystrophy
